Bottom line
Is ELIL a good fund? The bottom line
ELIL is a managed leveraged & inverse ETF from Direxion.
Annual fees run 1.07% — about $107 a year on every $10,000 invested, cheaper than 64% of leveraged & inverse funds we track.
With $18.3 million in net assets and 9 holdings, its largest position is Goldman Sachs Liq Es Fd A (32.5%) and the top 10 make up 96.1% of the portfolio.
What to watch
- Concentrated: top 10 holdings are 96.1% of assets
- Small fund ($18.3 million) — small funds are likelier to close
Updated Nov 19, 2026
What ELIL invests in
The Fund seeks daily investment results, before fees and expenses, of 200% of the daily performance of LLY. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day.
The Fund, under normal circumstances, invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of LLY and financial instruments, such as swap agreements and options, that, in combination, provide 2X daily leveraged exposure to LLY, consistent with the Funds investment objective. The financial instrument in which the Fund most commonly invests is swap agreements, which are intended to produce economically leveraged investment results. Eli Lilly and Company is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines in various therapeutic areas, including neuroscience, endocrinology, oncology, cardiovascular diseases, and immunology. Its portfolio encompasses a wide range of prescription drugs, biologics, and animal health products. LLY is registered under the Securities Exchange…
From the fund's prospectus (filed Mar 3, 2026).
What ELIL costs
On a $10,000 investment, ELIL's 1.07% expense ratio costs about $107 a year. The prospectus estimates $1,558 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.
ELIL top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Goldman Sachs Liq Es Fd A | 32.52% |
| 2 | Dreyfus | 25.97% |
| 3 | Dreyfus | 15.35% |
| 4 | Eli Lilly & Company LLY | 15.09% |
| 5 | Goldman Financial | 14.01% |
| 6 | N/a | 0.82% |
| 7 | N/a | 0.17% |
| 8 | N/a | -2.96% |
| 9 | N/a | -4.85% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 96.1% of the fund. See all top 25 holdings and asset mix →